Acute Myocardial Infarction With ST ElevationAIEWAEAMINCT07139860
Artificial Intelligence System for Early Warning of Adverse Events in Acute Myocardial Infarction
An observational study of Acute Myocardial Infarction With ST Elevation and Intelligent Management Platform, run by Hui Chen at 1 site in China.
Trial summary
The goal of this observational study is to learn about the effectiveness of an artificial intelligence-based early warning system for predicting adverse events in patients with acute myocardial infarction (AMI). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Myocardial Infarction With ST Elevation, Intelligent Management Platform, Early Warning
- How many people
- 1,400 participants
- Where
- 1 siteChina
- Study dates
- 26 Nov 2022to 31 Dec 2026
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: 1. Retrospective Study Population: Data were obtained from the Cardiovascular Center Database (CBDBank) of Beijing Friendship Hospital. CBDBank is a continuously collected sample dataset of patients with acute coronary syndrome since January 2013. A total of 1,000 patients with acute myocardial infarction admitted to Beijing Friendship Hospital, Capital Medical University, from January 2017 to December 2019 were included in the retrospective cohort. After discharge, all patients received scheduled telephone follow-ups at 1 month, 3 months, 6 months, and annually thereafter, with continuous follow-up for 3 years. 2. Prospective Study Population: A total of 800 patients with acute myocardial infarction admitted to the Cardiovascular Center of Beijing Friendship Hospital from July 2023 to July 2026 will be enrolled in the prospective cohort. Randomization will be performed using random codes, and prognosis prediction will be conducted using either the predictive system or traditional met
Who may be able to join
- 1. Hospitalized patients who meet the diagnostic criteria for acute myocardial infarction. 2. Patients who agree to participate and sign the informed consent form.
Who cannot join
- 1. Patients with terminal malignant tumors and an expected survival time of less than 3 months. 2. Patients with complete disability and inability to communicate. 3. Patients unable to comply with follow-up.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Beijing Friendship Hospital
Beijing, 100050
Hui Chen, +86 13910710028, 13910710028@163.com
About this study
The goal of this observational study is to learn about the effectiveness of an artificial intelligence-based early warning system for predicting adverse events in patients with acute myocardial infarction (AMI). The main question it aims to answer is:
Does an AI-based early warning system improve the assessment and prediction of adverse events across the full course of AMI care (from prevention to diagnosis, treatment, and rehabilitation)?
Participants who are receiving routine medical care for AMI in tertiary hospitals will have their multimodal medical data (clinical records, diagnostic tests, imaging, treatment pathways) collected and analyzed. Data will be integrated using innovative cross-modal representation methods and predictive models. The study will follow patients during their hospital stay and subsequent clinical follow-up to evaluate the feasibility, accuracy, and clinical value of the AI-based early warning system.
- Conditions
- Acute Myocardial Infarction With ST Elevation, Intelligent Management Platform, Early Warning
- Medical subject headings
- ST Elevation Myocardial Infarction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| BFH | group1 | |
| AZH | group2 |
What is being measured
The primary outcome is the main question the study is designed to answer.
MACCE
Cardiac death
All-cause mortality
Malignant arrhythmia
Non-fatal recurrent myocardial infarction
Non-fatal stroke
Unplanned repeat revascularization
Rehospitalization for heart failure
Measured: 1-3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Aug 2025
- Study start26 Nov 2022
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Myocardial Infarction With ST ElevationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 1,400 participants (estimated)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- Hui Chen
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Hui Chen, Beijing Friendship Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07139860
- Sponsor's protocol ID
- BFH2023063001
- Acronym
- AIEWAEAMI
- Status last verified
- Aug 2025
- First submitted
- 22 Aug 2025
- Last updated
- 24 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Artificial Intelligence System for Early Warning of Adverse Events in Acute Myocardial Infarction
- ClinicalTrials.gov ID
- NCT07139860
- Acronym / sponsor ID
- AIEWAEAMI / BFH2023063001
- Conditions
- Acute Myocardial Infarction With ST Elevation, Intelligent Management Platform, Early Warning
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,400 participants (estimated)
- Lead sponsor
- Hui ChenUniversity, hospital or other
- Study start
- 26 Nov 2022 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 24 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to learn about the effectiveness of an artificial intelligence-based early warning system for predicting adverse events in patients with acute myocardial infarction (AMI). The main question it aims to answer is:
Does an AI-based early warning system improve the assessment and prediction of adverse events across the full course of AMI care (from prevention to diagnosis, treatment, and rehabilitation)?
Participants who are receiving routine medical care for AMI in tertiary hospitals will have their multimodal medical data (clinical records, diagnostic tests, imaging, treatment pathways) collected and analyzed. Data will be integrated using innovative cross-modal representation methods and predictive models. The study will follow patients during their hospital stay and subsequent clinical follow-up to evaluate the feasibility, accuracy, and clinical value of the AI-based early warning system.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Target follow-up
- 1 Year
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| BFH | – | –group1 |
| AZH | – | –group2 |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- 1. Retrospective Study Population: Data were obtained from the Cardiovascular Center Database (CBDBank) of Beijing Friendship Hospital. CBDBank is a continuously collected sample dataset of patients with acute coronary syndrome since January 2013. A total of 1,000 patients with acute myocardial infarction admitted to Beijing Friendship Hospital, Capital Medical University, from January 2017 to December 2019 were included in the retrospective cohort. After discharge, all patients received scheduled telephone follow-ups at 1 month, 3 months, 6 months, and annually thereafter, with continuous follow-up for 3 years. 2. Prospective Study Population: A total of 800 patients with acute myocardial infarction admitted to the Cardiovascular Center of Beijing Friendship Hospital from July 2023 to July 2026 will be enrolled in the prospective cohort. Randomization will be performed using random codes, and prognosis prediction will be conducted using either the predictive system or traditional met
Key inclusion criteria (1 listed)
- 1. Hospitalized patients who meet the diagnostic criteria for acute myocardial infarction. 2. Patients who agree to participate and sign the informed consent form.
Key exclusion criteria (1 listed)
- 1. Patients with terminal malignant tumors and an expected survival time of less than 3 months. 2. Patients with complete disability and inability to communicate. 3. Patients unable to comply with follow-up.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
MACCE
Time frame: 1-3 years
Cardiac death All-cause mortality Malignant arrhythmia Non-fatal recurrent myocardial infarction Non-fatal stroke Unplanned repeat revascularization Rehospitalization for heart failure
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Aug 2025.
Related trials for Acute Myocardial Infarction With ST Elevation
RecruitingPhase 4
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
Acute Coronary Syndromes, STEMI
RecruitingPhase 2
Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction
Myocardial Infarction, Reperfusion Injury
Not yet recruitingObservational study
Incremental Prognostic Utility of CBC-derived Inflammatory Indices After Incomplete Coronary Revascularization: Association With 12-months Cardiovascular Outcomes
STEMI, High Risk NSTEMI
RecruitingObservational study
SuperSaturated Oxygen Comprehensive Observational Registry
STEMI - ST Elevation Myocardial Infarction, AMI
RecruitingPhase 4
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction
ST Elevation Myocardial Infarction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Myocardial Infarction With ST Elevation and Intelligent Management Platform, run by Hui Chen at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 24 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hui Chen (+86 13910710028, 13910710028@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
MACCE (time frame: 1-3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Aug 2025.